Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT02638090 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Non-small Cell Lung Cancer

Interventions

DRUG: Vorinostat
DRUG: Pembrolizumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]